The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The firm will use its solid-state nanopore technology to develop a point-of-care molecular diagnostic device to detect tuberculosis in low-resource areas.
In a wide-ranging discussion, the two leaders touched upon vaccine development, infant mortality, US education, research funding, machine learning, and precision medicine.
The award will support the development of diagnostics and analytical tools for childhood disease detection using tissue-based fluorescent in situ sequencing.
In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.
